Gufic Biosciences · NSE: GUFICBIO · BSE: 509079
Q2 FY25 results · Jul–Sep 2024
Gufic Biosciences reported revenue from operations of ₹204.18 crore (down 5.0% from Q2 FY24) and net profit of ₹21.77 crore (down 6.2% from Q2 FY24) for Q2 FY25 (Jul–Sep 2024), on a consolidated basis.
| Item | Q2 FY25 | Q2 FY24 | YoY | Q1 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 204.18 | 214.87 | −5.0% | 202.81 | +0.7% |
| Other income | 0.11 | 0.33 | −66.0% | 1.25 | −90.9% |
| Total income | 204.29 | 215.21 | −5.1% | 204.07 | +0.1% |
| Profit before tax | 29.25 | 30.95 | −5.5% | 28.10 | +4.1% |
| Net profit for the period | 21.77 | 23.21 | −6.2% | 20.86 | +4.4% |
| EPS, basic (₹) | 2.17 | 2.39 | −9.2% | 2.08 | +4.3% |
| Net margin (%) | 10.7 | 10.8 | 10.3 |
| Item | Q2 FY25 | Q2 FY24 | YoY | Q1 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 204.18 | 214.87 | −5.0% | 202.81 | +0.7% |
| Other income | 0.11 | 0.33 | −66.0% | 1.25 | −90.9% |
| Total income | 204.29 | 215.21 | −5.1% | 204.07 | +0.1% |
| Profit before tax | 29.26 | 30.95 | −5.4% | 28.11 | +4.1% |
| Net profit for the period | 21.78 | 23.21 | −6.2% | 20.86 | +4.4% |
| EPS, basic (₹) | 2.17 | 2.39 | −9.2% | 2.08 | +4.3% |
| Net margin (%) | 10.7 | 10.8 | 10.3 |
Consolidated
- Filed with BSE
- 15 Nov 2024, 15:42 IST
- Board meeting
- 14 Nov 2024
- Period
- 01 Jul 2024 to 30 Sep 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 15 Nov 2024, 15:42 IST
- Board meeting
- 14 Nov 2024
- Period
- 01 Jul 2024 to 30 Sep 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE